Infections due to resistant candida species in patients with cancer who are receiving chemotherapy

Clinical Infectious Diseases

Volumn 19, Issue , 1994, Pages S49-S53

  Wingard, John R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE;

CANCER; CANCER CHEMOTHERAPY; CANDIDIASIS; CONFERENCE PAPER; DRUG RESISTANCE; HUMAN; INFECTION COMPLICATION; INFECTION RISK; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, MICROBIAL; FLUCONAZOLE; HUMAN; ITRACONAZOLE; NEOPLASMS; POLYENES;

EID: 0028088090     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/clinids/19.Supplement_1.S49     Document Type: Article

References (43)

1. Karabinis A, Hill C. Leclercq B, Tancrede C, Baume D, Andremont A. Risk factors for candidemia in cancer patients: a case-control study. J Clin Microbiol 1988;26:429-32.
2. Richet HM, Andremont A, Tancrede C, Pico JL, Jarvis WR. Risk factors for candidemia in patients with acute lymphocytic leukemia. Rev Infect Dis 1989:13:211-5.
3. Bross J, Talbot GH, Maislin G. Hurwitz S, Strom BL. Risk factors for nosocomial candidemia: a case-control study in adults without leukemia. Am J Med 1989;87:614-20.
4. Craig JM, Färber S. Development of disseminated visceral mycosis during therapy for acute leukemia [abstract]. Am J Pathol 1953:29:601.
5. Zimmerman LE. Fatal fungus infections complicating other diseases. Am J Clin Pathol 1955;25:46-65.
6. Pizzo PA, Robichaud RN, Gill FA, et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101-10.
7. EORTC International Antimicrobial Therapy Cooperative Group. Km-piric antifungal therapy in febrile granulocytic patients. Am J Med 1989;86:668-72.
8. Dick JD, Merz WG, Sarai R. Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother 1980;18:158-63.
9. Merz WG, Sandford GR. Isolation and characterization of a polyene-resistant variant of Candida tropicalis. J Clin Microbiol 1979:9:67780.
10. Pappagianis D, Collins MS, Hector R, Remington J. Development of resistance to amphotericin B in Candida lusilaniae infecting a human. Antimicrob Agents Chemother 1979; 16:123-6.
11. Guinet R, Chanas J. Goullier A, Bonnefoy G, Ambroise-Thomas P. Fatal septicemia due to amphotericin B-resistant Candida lusilaniae. J Clin Microbiol 1983;18:443-4.
12. Merz WG. Candida lusilaniae: frequency of recovery, colonization, infection, and amphotericin B resistance. J Clin Microbiol 1984; 20:1194-5.
13. Dick JD, Rosengard BR, Merz WG, et al. Fatal disseminated candidiasis due to amphotericin B resistant Candida guilliennondi. Ann Intern Med 1985;102:67-8.
14. Hadfield TL, Smith MB, Winn RE. Mycoses caused by Candida lusilaniae. Rev Infect Dis 1987;9:1006-12.
15. Christenson JC. Guruswamy A, Mukwaya G, Rettig PJ. Candida lusilaniae: an emerging human pathogen. Pediatr Infect Dis J 1987; 6:755-7.
16. Powderly WG, Kobayashi GS, Herzig GP, Medoff G. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med 1988;84:826-32.
17. Kauffman CA. Bradley SF, Ross SC, Weber DR. Hepatosplenic candidiasis: successful treatment with fluconazole. Am J Med 1991; 91:137-41.
18. Anaissie E, Bodey GP, Kantarjian H. et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 1991;91:142-50.
19. Wingard JR. The useoffluconazolc prophylaxis in patients with ehemo-therapy-induced neutropenia. Leuk Lymphoma 1992;8:353-9.
20. Brammer KW. Management of fungal infection in neutropenic patients with fluconazole. Hamatol Bluttransfus 1990;33:546-50.
21. Goodman JL, Winston DJ. Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51.
22. Winston DJ. Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993; 118:495-503.
23. Wingard JR. Merz WG, Rinaldi MG, Johnson TR, Karp JE, Sarai R. Increase in Candida krusei among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991;325:1274-7.
24. Persons DA, Laughlin M, Tanner D, Perfect J, Gockerman JP, Hathorn JW. Fluconazole and Candida krusei fungemia [letter], N Engl J Med 1991:325:1315.
25. Casasnovas RO, Caillot D, Solary E, et al. Prophylactic fluconazole and Candida krusei infection [letter], N Engl J Med 1992;326:891-2.
26. Merz WG. Karp JE, Schron D, Sarai R. Increased incidence offunge-mia caused by Candida krusei. J Clin Microbiol 1986;24:581-4.
27. McQuillen DP, Zingman BS, Meunier F, Levitz SM. Invasive infections due to Candida krusei: report of ten cases of fungemia that include three cases of endophthalmitis. Clin Infect Dis 1992;14:472-8.
28. Berger C, Frei R, Gratwohl A, Tichelli A, Hafliger B, Speck B. A Candida krusei epidemic in a hematology department [in English], Schweiz Med Wochenschr 1988; 118:37-41.
29. Wingard JR. Merz WG, Rinaldi M, Karp JE, Sarai R. Antifungal prophylaxis in bone marrow transplantation, N Engl J Med 1992; 326:892-3.
30. Bignardi GE, Savage MA, Coker R, Davis SG. Fluconazole and Candida krusei infections [letter], J Hosp Infect 1991;18:326-7.
31. Mcllroy MA. Failure of fluconazole to suppress fungemia in a patient with fever, neutropenia and typhlitis [letter], J Infect Dis 1991; 163:420-1.
32. Edwards JE Jr. Montgomerie JZ, Ishida K, Morrison JO, Guze LB. Experimental hematogenous endophthalmitis due to Candida: species variation in ocular pathogenicity. J Infect Dis 1977;135:294-7.
33. Calderone RA, Scheid WM. Role of fibronectin in the pathogenesis of candidal infections. Rev Infect Dis 1987;9(suppl 4):S400-3.
34. King RD, Lee J C, Morris AL. Adherence of Candida albicans and other Candida species to mucosal epithelial cells. Infect Immun 1980:27:667-74.
35. Lee JC. King RD. Characterization of Candida albicans adherence to human vaginal epithelial cells in-vitro. Infect Immun 1983;41:1024-30.
36. Wingard JR. Merz WG, Rinaldi MG, Miller CB, Karp JE. Sarai R. Association of Torulopsis glabraia infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimi-crob Agents Chemothcr 1993;37:1847-9.
37. Hitchcock CA. Pye GW. Troke PF, Johnson EM, Warnock DW. Fluconazole resistance in Candida glabraia. Antimicrob Agents Che-mother 1993;37:1962-5
38. Vanden Bossche H. Marichal P. Odds FC, Le Jeune L, Coene MC. Characterization of an azole-resistant Candida glabiata isolate. Antimicrob Agents Chemother 1992;36:2602-10.
39. Warnock DW, Burke J, Cope N.I, Johnson EM, von Fraunhofer NA, Williams EW. Fluconazole resistance in Candida glabrala [letter]. Lancet 1988;2:1310.
40. Aisner J, Schimpff SC. Sutherland JC, Young VM. Wiernik PH. Torulopsis glabraia infections in patients with cancer. Am J Med 1976;61:23-8.
41. Wickerham LJ. Apparent increase in frequency of infections involving Torulopsis glabrala. JAMA 1957;165:47-8.
42. Persat F, Marzullo C, Guyotat D, Rochct MJ, Picns MA. Plasma itraconazole concentrations in neutropenic patients after repeated highdose treatment. Eur J Cancer 1992;28A:838-41.
43. Boken DJ. Swindells S, Rinaldi MG. Fluconazole-resistant Candida albicans. Clin Infect Dis 1993;17:1018-21.